A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms COAST
- Sponsors AstraZeneca; MedImmune
Most Recent Events
- 04 Jun 2024 Results (From Jan 2019 to Jul 2020, n=186) focusing on efficacy and safety , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 May 2024 According Innate Pharma media release, abstracts from this trial has been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.
- 15 May 2024 According to an innate pharma media release, AstraZeneca will present a poster at ASCO